All patients with hematologic disorders from a university teaching hospital in Belgium, who had BAL tested for galactomannan (GM) from 2005-2008, were reviewed. Only BAL samples obtained before the start of systemic antifungal therapy were used in the analysis.
Article Limit Reached
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content